TY - JOUR
T1 - Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer
AU - Amari, Masakazu
AU - Ishida, Takanori
AU - Takeda, Motohiro
AU - Ohuchi, Noriaki
N1 - Funding Information:
This work was supported in part by the Japanese Breast Cancer Society and Grant-in-aid for Cancer Research from the Ministry of Health, Labor and Welfare, Japan.
Funding Information:
Noriaki Ohuchi and Motohiro Takeda received research grant from Konica Minolta Medical & Graphics, Inc. Masakazu Amari and Takanori Ishida have no conflicts of interest.
PY - 2009/11/3
Y1 - 2009/11/3
N2 - Objective: Capecitabine is effective and well tolerated in patients with anthracycline and/or taxane-pre-treated metastatic breast cancer. We compared the efficacy and safety of capecitabine monotherapy between 1st, 2nd, 3rd and ≥4th line settings for advanced and metastatic breast cancer pre-treated with/without anthracycline and taxanes. Methods: Subjects comprised 84 patients with histologically confirmed advanced or metastatic breast cancer and at least one measurable metastatic lesion. We evaluated time to disease progression (TTP), response rate (RR) and clinical benefit rate (CBR) for 1st (n = 17), 2nd (n = 28), 3rd (n = 23) and ≥4th (n = 16) line setting treatments of capecitabine monotherapy. Results: Median number of cycles of capecitabine monotherapy was 12 cycles in 1st line, 11 cycles in 2nd line, 9 cycles in 3rd line and 11 cycles in ≥4th line. RR and CBR were 23.5% and 58.8% in 1st line, 21.4% and 53.6% in 2nd line, 21.7% and 52.2% in 3rd line, and 18.8% and 50.0% in ≥4th line, respectively. No significant differences in TTP were seen between each line setting (P = 0.843). Conclusions: Capecitabine monotherapy is effective and well tolerated in all line settings of chemotherapy in patients with metastatic or advanced breast cancer, and is suitable for outpatient therapy.
AB - Objective: Capecitabine is effective and well tolerated in patients with anthracycline and/or taxane-pre-treated metastatic breast cancer. We compared the efficacy and safety of capecitabine monotherapy between 1st, 2nd, 3rd and ≥4th line settings for advanced and metastatic breast cancer pre-treated with/without anthracycline and taxanes. Methods: Subjects comprised 84 patients with histologically confirmed advanced or metastatic breast cancer and at least one measurable metastatic lesion. We evaluated time to disease progression (TTP), response rate (RR) and clinical benefit rate (CBR) for 1st (n = 17), 2nd (n = 28), 3rd (n = 23) and ≥4th (n = 16) line setting treatments of capecitabine monotherapy. Results: Median number of cycles of capecitabine monotherapy was 12 cycles in 1st line, 11 cycles in 2nd line, 9 cycles in 3rd line and 11 cycles in ≥4th line. RR and CBR were 23.5% and 58.8% in 1st line, 21.4% and 53.6% in 2nd line, 21.7% and 52.2% in 3rd line, and 18.8% and 50.0% in ≥4th line, respectively. No significant differences in TTP were seen between each line setting (P = 0.843). Conclusions: Capecitabine monotherapy is effective and well tolerated in all line settings of chemotherapy in patients with metastatic or advanced breast cancer, and is suitable for outpatient therapy.
KW - Breast cancer
KW - Capecitabine
KW - Chemotherapy
KW - Monotherapy
UR - http://www.scopus.com/inward/record.url?scp=77950352457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950352457&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyp145
DO - 10.1093/jjco/hyp145
M3 - Article
C2 - 19887522
AN - SCOPUS:77950352457
VL - 40
SP - 188
EP - 193
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 3
M1 - hyp145
ER -
